Europe
Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.
MorphoSys AG reports results for the first quarter of 2019.
ADL Bionatur Solutions advances the results of selected key performance indicators for the first quarter of 2019 ending March 31, 2019.
Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019.
Paras Biopharmaceuticals Finland Oy is proud to announce that Reuters.com / Reuters Plus has selected our Finland-based company, working on biologics manufacturing & innovations in the healthcare segment as a valued contributor to the future of healthcare solutions.
Recipharm, the contract development and manufacturing organisation, has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.
Factory-CRO Group, a leading global contract research organization, is pleased to announce Sapna Hornyak as its new president and CEO and the appointment of Nick Thornton to chairman of its board of directors.
To Assess the Potential of Non-Opioid Treatment Options for Chronic Pain, Study Evaluates Pain Relief, Patient Function and Satisfaction
PDC*line is a potent, scalable and versatile professional antigen-presenting T-cell with great potential for treating a range of cancers
Company is now preparing a Series B funding round to finance the Phase 2 clinical program
PRESS RELEASES